First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

BACKGROUND: The KEYNOTE‐024 trial demonstrated that pembrolizumab, a PD‐1 inhibitor, significantly improves progression‐free survival (PFS) and overall survival (OS) in selected patients with previously untreated advanced non–small cell lung cancer (NSCLC) with a PD‐L1 tumor proportion score (TPS) ≥...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrane, Karim, Geier, Margaux, Corre, Romain, Léna, Hervé, Léveiller, Guillaume, Gadby, Florence, Lamy, Régine, Bizec, Jean‐Louis, Goarant, Eric, Robinet, Gilles, Gouva, Sylvie, Quere, Gilles, Abgral, Ronan, Schick, Ulrike, Bernier, Cyril, Chouaid, Christos, Descourt, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131849/
https://www.ncbi.nlm.nih.gov/pubmed/32022459
http://dx.doi.org/10.1002/cam4.2806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131849/
https://www.ncbi.nlm.nih.gov/pubmed/32022459
http://dx.doi.org/10.1002/cam4.2806

Ejemplares similares